x

Search for an orphan drug

* (*) mandatory field

Other search option(s)

Marketing authorisation without orphan designation - Europe

Therapeutic indication

- First-line treatment of patients with advanced renal cell carcinoma who have at least three of six prognostic risk factors.
- Treatment of adult patients with relapsed and/or refractory mantle cell lymphoma(MCL).

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.